• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CRYOLIFE, INC. ¿ KENNESAW BIOGLUE SYRINGE 5-PACK, 10 ML, JAPAN; GLUE,SURGICAL,ARTERIES

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CRYOLIFE, INC. ¿ KENNESAW BIOGLUE SYRINGE 5-PACK, 10 ML, JAPAN; GLUE,SURGICAL,ARTERIES Back to Search Results
Model Number BG3510-5-J
Device Problem Insufficient Information (3190)
Patient Problem Reaction to Medicinal Component of Device (4574)
Event Type  Injury  
Event Description
According to article, "a case of a coronary covered stent for repeated restenosis at the anastomosis site between saphenous vein graft and graft prosthesis" masaomi gohbara et al., "a (b)(6) man who had no past medical history suddenly felt back pain during a trip abroad and was diagnosed with urethral stone disease at the hospital.After 2 days of hospitalization, he returned to his country and was diagnosed with stanford type a acute aortic dissection on day 6.Emergent surgery [total arch replacement + aortic root replacement u graft 22 mm uapan life-line, tokyo, japan)] with a mechanical aortic valve [sjm regent 19mm (abbo.Tt, ca, usa)] and coronary artery reconstruction by a piehler method u graft 9 mm uapan life line, tokyo, japan)] was performed.His native right coronary artery (rca ) ostium and left main trunk (lmt) ostium were resected from his aortic root.Subsequently, his svg was used as a bypass graft from the j graft 9 mm uapan lifeline, tokyo, japan) to the posterior descending artery of the rca, and the distal end of j graft 9 mm uapan lifeline, tokyo, japan) was sutured to his lmt ostium (fig.1 ).Since it was difficult to control bleeding at the sutured anastomosis site between the svg and j graft 9 mm uapan lifeline, tokyo, japan), bioglue (cryo life, ga.Usa) surgical adhesive was used to control bleeding." "another mechanism was excessive inflammatory responses.Bioglue (cryolife, ga, usa) surgical adhesive, which has been widely used for vascular surgery, was used around the anastomosis site between the svg and j grafts uapan lifeline, tokyo, japan).Previous reports revealed that surgical sea lants, including bioglue (cryolife, ga, usa) surgical adhesive, had a side effect on inflammatory responses [5, 6].Bioglue (cryolife, ga, usa) surgical adhesive-induced inflammatory responses might cause vascular inflammation leading to excessive neointimal proliferation at the anastomosis site in the present case.".
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
BIOGLUE SYRINGE 5-PACK, 10 ML, JAPAN
Type of Device
GLUE,SURGICAL,ARTERIES
Manufacturer (Section D)
CRYOLIFE, INC. ¿ KENNESAW
1655 roberts blvd. nw
kennesaw GA 30144
Manufacturer (Section G)
CRYOLIFE, INC. ¿ KENNESAW
1655 roberts blvd. nw
kennesaw GA 30144
Manufacturer Contact
rochelle maney
1655 roberts blvd
kennesaw, GA 30144
7704193355
MDR Report Key12804774
MDR Text Key282281864
Report Number1063481-2021-00035
Device Sequence Number1
Product Code MUQ
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
P010003
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature,Company Representative
Reporter Occupation Other
Type of Report Initial,Followup,Followup
Report Date 01/07/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/12/2021
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Model NumberBG3510-5-J
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Distributor Facility Aware Date10/20/2021
Date Manufacturer Received10/20/2021
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age56 YR
Patient SexMale
-
-